CardioSeq: Impact of WGS in Individuals With CVD

Launched by ILLUMINA, INC. · Dec 15, 2022

Keywords

ClinConnect Summary

The TruGenome Cardiovascular Disease (CVD) test which consists of an in-silico 200 gene cardiovascular disease panel, a further 4 genes with cardiovascular disease risk alleles, 10 pharmacogenomic genes, 35 non-cardiovascular ACMG secondary finding genes and a polygenic risk score (PRS) for coronary artery disease (CAD) will be utilized in this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Individuals ≥18 years of age
• • 2. Stable ambulatory patients with a cardiology visit within the past year or scheduled within the next 90 days.
• 3. At least one of the following clinical diagnoses:
• • A. Any aortopathy, B. Dyslipidemia, C. Coronary or peripheral arterial disease, D. Heart Failure or cardiomyopathy, E. Any arrythmia
• • 4. Must be able to read, understand, and sign an informed consent
• Exclusion Criteria:
• • 1. Individuals with a previously confirmed molecular diagnosis of a known genetic disease with an associated cardiovascular phenotype inclusive of monogenic cardiovascular diseases, chromosomal aneuploidies, and microdeletion disorders.
• • 2. Bone marrow transplant recipients
• • 3. Individuals with severe cognitive dysfunction or diminished capacity who are unable to provide informed consent
• • 4. Patients undergoing active chemotherapy treatment for cancer
• • 5. Patients with end-stage renal disease
• • 6. Patients with poor medical prognosis with a life expectancy \<1 year
• • 7. Principal Investigator decides for any reason the study is not in the best interest of the patient